We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's product candidate consists of KarXT, for the treatment of acute psychosis in patients with schizophrenia, which are in clinical stage. Karuna Therapeutics Inc. is based in Boston, Massachusetts.
- Recent KRTX Stock Price: $161.33
- Yearly Gain for KRTX stock: 53.04%
- Market Cap for KRTX stock: $6.30B
- P/E Ratio for KRTX stock: -20.929
Will KRTX's stock price go up? Is there an accurate KRTX stock forecast available?
TipRanks.com reports that Karuna Therapeutics currently has 15 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $273.57. The target pricing ranges from a high KRTX forecast of $323.00 down to a low forecast of $209.00. Karuna Therapeutics (KRTX)’s last closing stock price was $161.33 which would put the average price target at 69.57% upside.
In addition, TradingView issued a Strong Sell rating for KRTX stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on KRTX stock.
Other analysts covering KRTX include:
- Jason Butler of JMP Securities issued a Buy rating with the price target of $ 323 on 23 hours ago
- Chris Howerton of Jefferies issued a Buy rating with the price target of $ 244 on 1 day ago
- Jason Gerberry of Bank of America Securities issued a Buy rating with the price target of $ 306 on 1 day ago
- Graig Suvannavejh of Mizuho Securities issued a Buy rating with the price target of $ 270 on 1 day ago
If you are wondering if KRTX is a good stock to buy, here are 3rd party ratings for KRTX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 37% (92 out of 248)
What is the sentiment on the street regarding Karuna Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for KRTX stock: Very Bullish
- Blogger Consensus for KRTX stock: Bullish
- Media Buzz for KRTX stock: Very High
- Insider Signal for KRTX stock: Neutral
- Investor Sentiment for KRTX stock: Positive
- Hedge Fund signal for KRTX stock: Positive
The stock market is extremely volatile, and you need to do your own research on KRTX stock including scouring the social networks like KRTX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for KRTX stock chart >>
Summary: MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON.
- Recent MLTX Stock Price: $22.01
- Yearly Gain for MLTX stock: 113.84%
- Market Cap for MLTX stock: $1.12B
- P/E Ratio for MLTX stock: -24.319
Will MLTX's stock price go up? Is there an accurate MLTX stock forecast available?
TipRanks.com reports that MoonLake Immunotherapeutics currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $28.00. The target pricing ranges from a high MLTX forecast of $36.00 down to a low forecast of $22.00. MoonLake Immunotherapeutics (MLTX)’s last closing stock price was $22.01 which would put the average price target at 27.21% upside.
In addition, TradingView issued a Buy rating for MLTX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on MLTX stock.
Other analysts covering MLTX include:
- Thomas Smith of SVB Securities issued a Buy rating with the price target of $ 28 on 1 day ago
- Prakhar Agrawal of Cantor Fitzgerald issued a Buy rating with the price target of $ 29 on 1 day ago
- Rami Katkhuda of LifeSci Capital issued a Buy rating with the price target of $ 25 on 1 day ago
- Julian Harrison of BTIG issued a Buy rating with the price target of $ 36 on 2 days ago
If you are wondering if MLTX is a good stock to buy, here are 3rd party ratings for MLTX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 37% (92 out of 248)
What is the sentiment on the street regarding MoonLake Immunotherapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for MLTX stock: Very Bullish
- Blogger Consensus for MLTX stock: ―
- Media Buzz for MLTX stock: Very High
- Insider Signal for MLTX stock: ―
- Investor Sentiment for MLTX stock: ―
- Hedge Fund signal for MLTX stock: Neutral
The stock market is extremely volatile, and you need to do your own research on MLTX stock including scouring the social networks like MLTX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MLTX stock chart >>
Summary: Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.
- Recent ALT Stock Price: $4.95
- Yearly Gain for ALT stock: 56.22%
- Market Cap for ALT stock: $538.13M
- P/E Ratio for ALT stock: -6.151
Will ALT's stock price go up? Is there an accurate ALT stock forecast available?
TipRanks.com reports that Altimmune currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $27.38. The target pricing ranges from a high ALT forecast of $50.00 down to a low forecast of $6.00. Altimmune (ALT)’s last closing stock price was $4.95 which would put the average price target at 453.13% upside.
In addition, TradingView issued a Strong Sell rating for ALT stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALT stock.
Other analysts covering ALT include:
- Jonathan Wolleben of JMP Securities issued a Buy rating with the price target of $ 26 on 23 hours ago
- Corinne Jenkins of Goldman Sachs issued a Hold rating with the price target of $ 6 on 23 hours ago
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $ 26 on 23 hours ago
- Patrick Trucchio of H.C. Wainwright issued a Buy rating with the price target of $ 50 on 23 hours ago
If you are wondering if ALT is a good stock to buy, here are 3rd party ratings for ALT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 35% (86 out of 248)
What is the sentiment on the street regarding Altimmune? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALT stock: Very Bullish
- Blogger Consensus for ALT stock: Bullish
- Media Buzz for ALT stock: Very High
- Insider Signal for ALT stock: ―
- Investor Sentiment for ALT stock: Negative
- Hedge Fund signal for ALT stock: Negative
The stock market is extremely volatile, and you need to do your own research on ALT stock including scouring the social networks like ALT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALT stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
